Agios Pharmaceuticals (AGIO) Competitors

Agios Pharmaceuticals (NASDAQ:AGIO) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Do analysts rate AGIO or ELAN?

Agios Pharmaceuticals currently has a consensus price target of $56.33, indicating a potential upside of 47.55%. Elanco Animal Health has a consensus price target of $17.33, indicating a potential downside of 6.17%. Given Agios Pharmaceuticals' higher possible upside, research analysts plainly believe Agios Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Elanco Animal Health	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

Does the media prefer AGIO or ELAN?

In the previous week, Elanco Animal Health had 9 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 15 mentions for Elanco Animal Health and 6 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 1.68 beat Elanco Animal Health's score of 0.71 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Elanco Animal Health	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AGIO or ELAN more profitable?

Agios Pharmaceuticals has a net margin of 1,590.42% compared to Elanco Animal Health's net margin of 9.68%. Elanco Animal Health's return on equity of 7.04% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	1,590.42%	-3.49%	-3.23%
Elanco Animal Health	9.68%	7.04%	3.45%

Do insiders & institutionals hold more shares of AGIO or ELAN?

97.5% of Elanco Animal Health shares are held by institutional investors. 4.3% of Agios Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has better earnings and valuation, AGIO or ELAN?

Agios Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$36.50M	60.77	$673.72M	$11.00	3.47
Elanco Animal Health	$4.44B	2.07	$338M	$0.86	21.48

Which has more volatility & risk, AGIO or ELAN?

Agios Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Summary

Elanco Animal Health beats Agios Pharmaceuticals on 9 of the 17 factors compared between the two stocks.